Can a pill tackle Tough-to-Treat leukemia?

NCT ID NCT07751991

Recruiting now Disease control Sponsor: Charm Therapeutics Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to find a safe dose, understand side effects, and see how the body processes the drug. Participants receive increasing doses of CHM-029 and are monitored with blood tests, ECGs, and bone marrow checks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHM-029, an investigational oral drug
What this could lead to: If successful, this could lead to a new oral treatment option for adults with hard-to-treat AML that has specific genetic changes.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not work as hoped or may cause unexpected side effects. The results will need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.